Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
The present invention relates to genetically engineered cell populations derived from an immortalised/cancerous cell that do not express MHC class I molecules but that are modified to express membrane-bound IL-15, membrane-bound 4-1 BBL ligand, and at least one other membrane bound molecule, such as an interleukin or anti-CD3 antibody. The co-culture of said cells with a population of immune cells results in the activation and expansion of at least one subpopulation of immune cells. Expanded populations of NK cells derived from the co-culture of a mixed cell culture with the stimulatory cell lines may be used in methods of treating cancer or an infectious disease. In a separate embodiment, a plurality of nucleic acids for use in preparing the engineered cell population are provided.
1. A genetically engineered cell population that does not express major histocompatibility complex (MHC) I molecules,
wherein said genetically engineered cell population is derived from K562 cells,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 comprises the amino acid sequence of SEQ ID NO: 2,
wherein said genetically engineered cell population is modified to express membrane-bound 4-1BB ligand (mb4-1BBL) comprising the amino acid sequence of SEQ ID NO: 14,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-18 (mbIL18), wherein the mbIL18 comprises the amino acid sequence of SEQ ID NO: 8,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12A (mbIL12A), wherein the mbIL12A comprises the amino acid sequence of SEQ ID NO: 4,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12B (mbIL12B), wherein the mbIL12B comprises the amino acid sequence of SEQ ID NO: 6,
wherein said genetically engineered cell population does not express major histocompatibility complex (MHC) I molecules, and
wherein co-culture of said genetically engineered cell population with a population of natural killer (NK) cells results in the activation and expansion of the NK cells.
2. The genetically engineered cell population of claim 1 , wherein the genetically engineered cell population lacks expression of MHC II molecules.
3. The genetically engineered cell population of claim 1 , wherein the genetically engineered cell population is further modified to express:
membrane-bound interleukin-21 (mbIL21) comprising the sequence of SEQ ID NO: 10; or
membrane-bound interleukin-22 (IL22) comprising the sequence of SEQ ID NO: 12.
4. The genetically engineered cell population of claim 1 , wherein the cells further comprise a membrane-bound anti-CD3 antibody (mbα-CD3), an antibody fragment thereof, or an anti-CD3 scFv.
5. The genetically engineered cell population of claim 4 , wherein the mbα-CD3 is a monoclonal antibody.
6. The genetically engineered cell population of claim 5 , wherein the mbα-CD3 targets an epitope within the epsilon subunit of the CD3 receptor.
7. A genetically engineered cell population that does not express major histocompatibility complex (MHC) I molecules,
wherein said genetically engineered cell population is derived from K562 cells,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 is encoded by a nucleic acid sequence that comprises SEQ ID NO: 1,
wherein said genetically engineered cell population is modified to express membrane-bound 4-1BB ligand (mb4-1BBL) comprising the amino acid sequence of SEQ ID NO: 14,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-18 (mbIL18), wherein the mbIL18 comprises the amino acid sequence of SEQ ID NO: 8,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12A (IL12A), wherein the mbIL12A comprises the amino acid sequence of SEQ ID NO: 4,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12B (IL12B), wherein the mbIL12B comprises the amino acid sequence of SEQ ID NO: 6,
wherein said genetically engineered cell population does not express major histocompatibility complex (MHC) I molecules, and
wherein co-culture of said genetically engineered cell population with a population of natural killer (NK) cells results in the activation and expansion of the NK cells.
8. The genetically engineered cell population of claim 7 , wherein the amino acid sequence of SEQ ID NO:14 is encoded by a nucleic acid sequence that comprises SEQ ID NO: 13.
9. The genetically engineered cell population of claim 7 , wherein the engineered cell population is further modified to express membrane-bound interleukin-21 or membrane-bound interleukin-22.